Daniel J. Lippis Sells 400 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis sold 400 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the sale, the vice president now directly owns 22,588 shares in the company, valued at $1,569,414.24. The trade was a 1.74 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Edwards Lifesciences Stock Down 0.1 %

Shares of Edwards Lifesciences stock opened at $68.49 on Wednesday. The company has a market cap of $40.26 billion, a price-to-earnings ratio of 9.83, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company’s 50 day moving average is $72.03 and its 200 day moving average is $70.35. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Institutional Trading of Edwards Lifesciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EW. Leavell Investment Management Inc. increased its holdings in Edwards Lifesciences by 3.3% during the third quarter. Leavell Investment Management Inc. now owns 9,923 shares of the medical research company’s stock valued at $655,000 after buying an additional 321 shares during the last quarter. Ownership Capital B.V. increased its holdings in Edwards Lifesciences by 1.2% during the third quarter. Ownership Capital B.V. now owns 2,993,019 shares of the medical research company’s stock valued at $197,509,000 after buying an additional 34,597 shares during the last quarter. State of New Jersey Common Pension Fund D increased its holdings in Edwards Lifesciences by 3.1% during the third quarter. State of New Jersey Common Pension Fund D now owns 226,465 shares of the medical research company’s stock valued at $14,944,000 after buying an additional 6,723 shares during the last quarter. Kennebec Savings Bank purchased a new stake in Edwards Lifesciences during the third quarter valued at approximately $79,000. Finally, Patten & Patten Inc. TN increased its holdings in Edwards Lifesciences by 7.5% during the third quarter. Patten & Patten Inc. TN now owns 164,904 shares of the medical research company’s stock valued at $10,882,000 after buying an additional 11,512 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Canaccord Genuity Group boosted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday, February 12th. Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Finally, Citigroup boosted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.